SWAV — Shockwave Medical Cashflow Statement
0.000.00%
Last trade - 00:00- $12.57bn
- $12.27bn
- $730.23m
Annual cashflow statement for Shockwave Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -51.1 | -65.7 | -9.14 | 216 | 147 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.16 | 13 | 37.1 | 52.1 | 67.5 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.49 | -20.3 | -16.5 | -57.9 | -43.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -48.1 | -71.2 | 15 | 118 | 196 |
| Capital Expenditures | -3.82 | -11.5 | -12.4 | -25.1 | -30.6 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -55.7 | -96 | 38.9 | -37 | -595 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -59.5 | -107 | 26.4 | -62.1 | -626 |
| Financing Cash Flow Items | 10 | -1.6 | -8.34 | -0.023 | -16.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 208 | 90 | -2.45 | 13 | 600 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 100 | -88.6 | 39 | 67.4 | 172 |